Cellular therapy in pancreatic cancer
10.3781/j.issn.1000-7431.2024.2409-0538
- VernacularTitle:胰腺癌的细胞治疗
- Author:
Chengyang HU
1
;
Qi ZHANG
;
Tingbo LIANG
Author Information
1. 浙江大学医学院附属第一医院肝胆胰外科,浙江 杭州 310003;教育部胰腺疾病国际合作联合实验室,浙江 杭州 310003;全省胰腺病研究重点实验室,浙江 杭州 310003
- Publication Type:Journal Article
- Keywords:
Pancreatic cancer;
Cell therapy;
Immunotherapy;
Chimeric antigen receptor T cell immuno-therapy;
T cell receptor
- From:
Tumor
2024;44(12):1191-1208
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer has an insidious onset and a high degree of malignancy,and due to the limited efficacy of traditional treatments such as surgery and chemotherapy,this tumor has been one of the malignant tumors with the highest morbidity and mortality rates.In recent years,cell therapy,which utilizes and modifies the patient's own immune cells to target and kill tumor cells,is gradually becoming one of the potential alternatives to traditional treatment of tumors,and has achieved positive results in hematologic tumors.However,cell therapy in solid tumors,such as pancreatic cancer,is still in the research stage,and although it has achieved some efficacy,it is still full of challenges.In this review,the mechanism of chimeric antigen receptor-T cells(CAR-T),T cell receptor-T cells(TCR-T),and tumor infiltrating lymphocytes(TILs)in cell therapy and the efficacy in the treatment of pancreatic cancer were thoroughly discussed.Meanwhile,the main reasons for the poor effect of cell therapy in pancreatic cancer and the current research progress in improving the effect of cell therapy are preliminarily analyzed.
